Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Jonathan Ledermann

26PUBLICATIONS
88CO-AUTHORS
Molecular targetsCancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

Sort by Publication Date:
|Jun 18, 2025
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.

Uma A Mukherjee, Rowan E Miller, Jonathan A Ledermann

|Nov 09, 2024
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London.

Karim H El-Shakankery, Joanna Kefas, Kieran Palmer

|Oct 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Lucy Haggstrom, Yeh Chen Lee, Clare Scott

|Sep 04, 2024
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population<sup>☆</sup>.

Eve Merry, Ronas Taner Kesmez, Tamara Yu

|May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).

Agnieszka Michael, William Wilson, Sunny Sunshine

|Jan 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.

Angelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann

Pageof 5

Frequent Collaborators

3 joint publications

Christina Fotopoulou

3 joint publications

Michael L Friedlander

3 joint publications

Osnat Elyashiv

3 joint publications

Robert L Coleman

2 joint publications

Karim H El-Shakankery

2 joint publications

Rowan Miller

2 joint publications

Shibani Nicum

2 joint publications

Nicole Concin

2 joint publications

Uma Mukherjee

2 joint publications

Yeh Chen Lee

Frequent Collaborators

3 joint publications

Christina Fotopoulou

3 joint publications

Michael L Friedlander

3 joint publications

Osnat Elyashiv

3 joint publications

Robert L Coleman

Top Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids <em>via</em> Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids <em>via</em> Immunofluorescence Assays

Published on : Feb 24, 2023

1.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on : Oct 25, 2011

18.6K
See more related videos

Top Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids <em>via</em> Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids <em>via</em> Immunofluorescence Assays

Published on : Feb 24, 2023

1.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on : Oct 25, 2011

18.6K
See more related videos